Patients with severe concomitant diseases, who are mainly excluded from randomized, prospective, cardiovascular trials, such as CABG, severe renal insufficiency (GFR between 25 and 50 ml/min/1.73 m2), patients receiving insulin treatment are all represented in this trial. The gene discussed is INS; the disease is Renal insufficiency.